21:38 , Feb 23, 2017 |  BC Innovations  |  Tools & Techniques

Showdown: bacteria vs. virus

Drug developers are starting to revisit bacteriophages as a solution for two of the biggest questions in translational research: how to treat resistant bacterial infections, and how to manipulate the human microbiome. A spate of...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Company News

AmpliPhi BioSciences, Special Phage deal

AmpliPhi will acquire Special Phage in a stock deal under which AmpliPhi has offered up to 40 million shares to Special Phage. The shares are valued at up to $4.4 million based on AmpliPhi's Sept....
08:00 , Mar 5, 2012 |  BioCentury  |  Strategy

Funding the white space

Celladon Corp. found no pharma partners for its Mydicar gene therapy following data from a small Phase I/II trial in advanced heart failure patients, but the results prompted the venture arms of three of the...
07:00 , May 2, 2011 |  BC Week In Review  |  Clinical News

CardioFit system: Phase III started

BioControl began the open-label, U.S. and German Phase III INOVATE-HF trial to evaluate CardioFit plus standard of care (SOC) vs. SOC alone in about 650 patients. BioControl Medical Ltd. , Yehud, Israel   Product: CardioFit...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Targeted Genetics management update

Targeted Genetics Corp. (Pink:TGEN), Seattle, Wash.   Business: Gene/Cell therapy, Autoimmune, Infectious   Hired: Edward Cappabianca as CEO, formerly CEO of Biocontrol Ltd. , which Targeted Genetics acquired; and David Harper as CSO, formerly CSO...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Biocontrol, Targeted Genetics deal

Targeted Genetics completed its previously announced acquisition of infectious disease company Biocontrol in a stock deal. Biocontrol shareholders received 22.6 million shares of Targeted Genetics valued at $8.6 million based on Targeted Genetics' close of...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

Biocontrol, Targeted Genetics deal

Targeted Genetics will acquire infectious disease company Biocontrol in a stock deal. Biocontrol shareholders will receive 22.6 million shares of Targeted Genetics' common stock, valued at $10.2 million based on Targeted Genetics' close of $0.45...
08:00 , Nov 3, 2003 |  BC Week In Review  |  Company News

BioControl Systems Inc., Epoch Biosciences deal

BioControl received a non-exclusive license to EBIO's MGB Eclipse technologies, and an exclusive license to specific probe sequences for inclusion in BioControl's food safety test kits. Epoch will receive technology access fees, product sales from...
07:00 , Jun 12, 2000 |  BC Week In Review  |  Company News

Biocontrol Technology Inc. management update

Biocontrol Technology Inc. (BICO), Pittsburgh, Penn.   Business: Diagnostics/Imaging   Transition: David Purdy to president and CEO of BICO's biomedical division from chairman of BICO  ...
07:00 , May 30, 2000 |  BC Week In Review  |  Clinical News

Diasensor 2000 glucose monitor regulatory update

BICO received CE Mark approval for European marketing of its noninvasive glucose monitor that uses near infrared light. Biocontrol Technology Inc. (BICO), Pittsburgh, Penn.   Product: Diasensor 2000 glucose monitor   Business: Diagnostics/Imaging  ...